Alpha-isoform selective phosphatidylinositol 3-kinase inhibitor dosing regimen

摘要

The present invention relates to an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof for use in a method of treating or preventing a proliferative disorder in a patient in need thereof Wherein said method comprises a therapeutically effective amount of an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof for at least two 5-day continuous cycles The compound or a pharmaceutically acceptable salt thereof, wherein the compound is administered orally into the compound and is not administered to the patient for a period of about 2 to about 3 days during the 5-day continuous cycle.